Navigation Links
Real-world patient survival with defibrillators matches trial expectations
Date:1/1/2013

DURHAM, N.C. Patients who received an implantable heart defibrillator in everyday practice had survival benefits on par with those who received the same devices in carefully controlled clinical trials, according to a new study that highlights the value of defibrillators in typical medical settings.

Led by the Duke Clinical Research Institute and published Jan. 2, 2013, in the Journal of the American Medical Association, the study used data from a large national Medicare registry to assess the survival of patients receiving defibrillators, which are commonly used to prevent sudden cardiac death.

Because clinical trial participants tend to receive more meticulous care while also being healthier than patients seen in clinical practice, the actual benefits of new drugs and medical devices can be less positive than initially reported. Not so for the defibrillators, at least when comparing patients with similar characteristics in both the clinical trials and real-world practice.

"Many people question how the results of clinical trials apply to patients in routine practice," said lead author Sana M. Al-Khatib, M.D., MHS, an electrophysiologist and member of the Duke Clinical Research Institute. "We showed that patients in real-world practice who receive a defibrillator but who are most likely not monitored at the same level provided in clinical trials have similar survival outcomes compared to patients who received a defibrillator in the clinical trials."

"This study demonstrated the real-world applicability of the results of recent randomized clinical trials," said Alice Mascette, M.D., of the NIH's National Heart, Lung, and Blood Institute.

Implantable cardioverter-defibrillators (ICDs) have been lifesavers for people with a history of cardiac arrest or heart failure. The devices, small electrical units implanted in the chest with wires that lead into the heart, send an electronic pulse when the heart stops beatin
'/>"/>

Contact: Rachel Harrison
rachel.harrison@duke.edu
919-419-5069
Duke University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Little evidence to support TB interventions in real-world, low-resource settings
2. FOTO, Inc. Automates PQRS and Functional Limitation Calculation With Patient Inquiry
3. Case Western Reserve University receives patient-centered research award
4. Patient-Centered Outcomes Research Institute announces 2 awards to Group Health
5. Drug shortage linked to greater risk of relapse in young Hodgkin lymphoma patients
6. MRI can screen patients for Alzheimers disease or frontotemporal lobar degeneration
7. Texas Clinic Now Accepting Brachial Plexus Patients; Children and Adults
8. Sustained virological response linked with improved survival for patients with chronic HCV infection
9. Patient Survival Rises When Drugs Suppress Hepatitis C in Blood: Study
10. New Metal-on-Metal Hip Implant Study Emphasizes Importance of Patients’ Symptoms in Evaluating the Need for Hip Replacement Revisions, Bernstein Liebhard LLP Reports
11. Big transfusions add risk for heart attack patients with anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... of the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ... Liebhard LLP reports. According to an Order issued in ... November 20th, the Court will convene an open conference ... Federal Building and United States Courthouse in West Palm ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... illnesses can receive effective, less expensive care from a clinic ... a team of dedicated health care professionals, a new study ... and need either hospitalization or a trip to the emergency ... clinic at the University of Texas in Houston versus usual ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 AngelWeddingDress.com tries ... to the online realm. Today, the business has introduced ... a site-wide prom dress promotion. , The new prom ... each and every dress lover. They are specially designed ... 2015 prom dresses should visit its website before ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... five cities in one ... ... of the Institute for Integrative Nutrition, the world,s largest,nutrition school, is hosting ... 14. He will demystify the confusion people,experience from all the different dietary ...
... WILMINGTON, Del., May 14 AstraZeneca (NYSE:,AZN) today ... (FDA) has,approved SEROQUEL(R) (quetiapine fumarate tablets) for the ... adjunct therapy to,lithium or divalproex. SEROQUEL is approved ... is also the only single agent approved by ...
... BOULDER, Colo., May 14 Green tea consumption may,promote ... addition,to supporting the medical treatment of some kinds of ... of Alternative Therapies in Health and,Medicine, on newsstands now., ... has anti-cancerous potential,in human stomach and colon cancers, 6 ...
... DUBLIN, May 14 Amarin Corporation plc,(NASDAQ: ... American Depositary,Shares (each representing one ordinary share) ("ADSs") ... certain directors,of the Company, for up to $60 ... new investors, who have entered into definitive agreements ...
... physicians,researchers, Wall Street analysts and industry executives will gather ... 30 - June 1, 2008. With,the most comprehensive and ... this unique venue is focused on,accelerating and sustaining the ... "THE Aesthetic Show offers a weekend immersion in ...
... SYDNEY, Australia, May 14 /PRNewswire-FirstCall/,-- HeartWare Limited (ASX: HTW) ... presentation at the Seventh Annual JMP Securities Research,Conference at ... 21, 2008. The,conference is being held at the Ritz-Carlton, ... the Company,s presentation at the conference will be,available via ...
Cached Medicine News:Health News:Institute for Integrative Nutrition Begins Road Tour 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 3Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 4Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 5Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 6Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 7Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 8Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 9Health News:Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer 2Health News:Amarin Announces Private Placement for up to $60 Million 2Health News:Amarin Announces Private Placement for up to $60 Million 3Health News:Amarin Announces Private Placement for up to $60 Million 4Health News:Amarin Announces Private Placement for up to $60 Million 5Health News:THE Aesthetic Show Advances $34 Billion Market 2Health News:THE Aesthetic Show Advances $34 Billion Market 3Health News:HeartWare to Present at Seventh Annual JMP Securities Research Conference 2
(Date:12/22/2014)... , Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... the treatment and management of epilepsy, today announced it will ... Conference on Wednesday, January 14, 2015, in San ... President and Chief Executive Officer, will speak at 11:00 AM ... be accessed by clicking on the Investor Relations link on ...
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... campaign launched today highlights the clear choice policymakers in states ... Medicaid program: cut benefits for patients or billions in overpayments ... save $33 billion over the next decade by cutting ... like those in Medicare and commercial plans. ...
... RENO, Nev., June 15, 2011 Visual Healthcare Corp. (the ... announce today that it expects revenues for the fourth quarter ... mid-range of the current guidance is a record high since ... 2011. Based on these figures the Company can provide further ...
Cached Medicine Technology:The Medicaid Choice: Cut Benefits for Patients or Overpayments to Independent Drugstores 2Visual Healthcare Provides Fourth Quarter Revenue Guidance 2
... only control for monitoring total ... fluid samples performed manually using ... an aid for identifying the ... pathological condition present in the ...
... use with Leica Unistat and ... and all automated bilirubin methods ... AU Series, Cobas, Dimension, Hitachi, ... contain purified bilirubin in a ...
... The Dropper Plus is specifically designed for ... room temperature stability eliminates storage problems and ... without refrigeration. A new feature is the ... provided for all analytes; qualitative results for ...
... the ultimate in convenience for urinalysis quality ... DipandSpin is a combination product for dipstick, ... feature is the addition of creatinine and ... as well as for all analytes; qualitative ...
Medicine Products: